Alternative Dosing Regimens of Subcutaneous Azacitidine for Myelodysplastic Syndromes

NCT00102687 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
151
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Celgene